Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis.
Eslam Mohammed RabeaMohamed Mohamed BelalAbdelrahman H HafezAshraf Hassan ElbannaMahmoud Ahmed KhalifaAnas Zakarya NoureldenNada H MahmoudMohamed Sayed ZaazoueePublished in: Acta neurologica Belgica (2024)
In summary, our meta-analysis indicates that natalizumab maintains its effectiveness under extended interval dosing [up to 8 weeks], presenting comparable risks for clinical relapses, MRI lesions, EDSS, and PML. Caution is advised given study limitations and heterogeneity. Robust conclusions necessitate well-designed high-quality prospective studies.
Keyphrases
- multiple sclerosis
- systematic review
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- magnetic resonance imaging
- white matter
- case control
- prognostic factors
- single cell
- magnetic resonance
- contrast enhanced
- case report
- meta analyses
- patient reported outcomes
- risk assessment